|
Welcome to NuVue Therapeutics, Inc., a medical device, diagnostics, and drug delivery company with an initial focus on accurate diagnosis and targeted treatment of liver, pancreatic, and other hard-to-treat soft-tissue cancers.
NuVue receives FDA 510(k) Approval for ColorMarkTM Biopsy Needles
Fairfax, VA, March 8, 2011 – NuVue Therapeutics, Inc., has received FDA “510(k)” approval for its first ColorMark™ Biopsy Needles, the company announced today. [See News.] Contact us to preorder a supply of ColorMark™-A Biopsy Needles for your institution or practice.
NuVue receives "Best Life Sciences Company" Award
Somerset, NJ, March 25, 2011 - NuVue Therapeutics, Inc., received the “Best Life Sciences Company” award at the 2011 New Jersey Technology Council Venture Conference. [See News]
|
NuVue’s diagnostic products are designed to give a bright, clear image of biopsy needles in real-time during a procedure, and to accurately mark the site for further imaging and/or biopsies.
NuVue’s therapeutic products are designed to avoid the toxic effects of systemic chemotherapy by providing targeted delivery of free and encapsulated drugs and cryothermal effects directly into the tumor. Using only 1/200 – 1/500 of a systemic dose, these products will avoid the toxic side effects of standard chemotherapy, sparing the patient’s immune system and providing a better quality of life during and after therapy. NuVue’s therapeutics will treat all soft tissue cancers.
When combined, these diagnostic and therapeutic products will produce a powerful, integrated system for site-specific treatment of all soft-tissue cancers.
|
|
|
